From the report
Dr. Stamler, continued, “In the ATH434-202 trial, the participants who stabilized or improved with ATH434 treatment had less advanced disease than those who progressed.
That is the bit I remember
- Forums
- ASX - By Stock
- ATH
- News, articles and interviews
ATH
alterity therapeutics limited
Add to My Watchlist
6.25%
!
0.9¢
News, articles and interviews, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
The Watchlist
OR3
ORE RESOURCES LIMITED
Nicholas Rathjen, Managing Director
Nicholas Rathjen
Managing Director
SPONSORED BY The Market Online